Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | COLUMBA: SC vs IV daratumumab in R/R multiple myeloma

Joan Bladé • 15 Jun 2019
EHA 2019
Multiple Myeloma
COLUMBA

Joan Bladé, MD, Hospital Clinic, Barcelona, Spain, discusses the use of subcutaneous daratumumab compared to intravenous daratumumab in the treatment of relapsed/refractory multiple myeloma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Joan Bladé

Looking forward to ISA 2022 2:36
Looking forward to ISA 2022
Joan Bladé • 12 May 2022
How the amyloidosis treatment landscape has transformed in recent years 1:02
How the amyloidosis treatment landscape has transformed in recent years
Joan Bladé • 12 May 2022
Managing and treating renal impairment in multiple myeloma 3:26
Managing and treating renal impairment in multiple myeloma
Joan Bladé • 12 May 2022
Amyloidosis classification and epidemiology 3:05
Amyloidosis classification and epidemiology
Joan Bladé • 4 Sep 2020

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals